Signal
BioNTech and DualityBio Evaluate HER2 ADC Strategy Following Modest Phase 3 Results
- Category
- · Research · Global
- Date
- October 26, 2026
- Source
- OVUM
Summary
BioNTech and DualityBio are reassessing the development path for trastuzumab pamirtecan (BNT323/DB-1303) after Phase 3 trial data in HER2-low breast cancer showed statistically significant but underwhelming efficacy compared to established competitors like Enhertu.
The finding adds to the evidence in Oncology. Read it alongside earlier studies asking the same question. Companies whose products depend on clinical proof feel this kind of result first.
OVUM interpretation layer
The editorial read on this signal — pattern, market-structure implications, and what to watch next.
Sources
- OVUM Primary source
The OVUM Intelligence Brief
Keep reading past this page
The week's funding, launches, and studies in women's health, in plain English.
Weekly. No spam. Unsubscribe anytime.